XLON
POLX
Market cap20mUSD
May 30, Last price
1.27GBP
1D
0.00%
1Q
-2.31%
IPO
-92.06%
Name
Polarean Imaging PLC
Chart & Performance
P/E
—
P/S
2,314.98
EPS
—
Div Yield, %
—
Shrs. gr., 5y
29.14%
Rev. gr., 5y
-18.24%
Revenues
891k
-13.75%
Net income
-12m
L-15.95%
CFO
-10m
L-14.87%
Earnings
Jun 26, 2025
Profile
Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 891 -13.75% | 1,033 -12.86% | ||||||
Cost of revenue | 11,650 | 13,079 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (10,759) | (12,046) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 235 | |||||||
Tax Rate | ||||||||
NOPAT | (10,759) | (12,281) | ||||||
Net income | (11,885) -15.95% | (14,141) 3.10% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 18 | 267 | ||||||
BB yield | -0.12% | -0.23% | ||||||
| Debt | ||||||||
Debt current | 142 | 142 | ||||||
Long-term debt | 292 | 576 | ||||||
Deferred revenue | 67 | 129 | ||||||
Other long-term liabilities | 240 | 676 | ||||||
Net debt | (5,738) | (15,737) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (10,435) | (12,258) | ||||||
CAPEX | (79) | (64) | ||||||
Cash from investing activities | 220 | (64) | ||||||
Cash from financing activities | (140) | 148 | ||||||
FCF | (10,057) | (12,661) | ||||||
| Balance | ||||||||
Cash | 6,172 | 16,454 | ||||||
Long term investments | ||||||||
Excess cash | 6,127 | 16,403 | ||||||
Stockholders' equity | (64,546) | (39,983) | ||||||
Invested Capital | 73,368 | 60,452 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 251,207 | 211,949 | ||||||
Price | 0.06 -88.84% | 0.56 -0.88% | ||||||
Market cap | 15,700 -86.77% | 118,691 6.66% | ||||||
EV | 9,962 | 102,955 | ||||||
EBITDA | (9,822) | (11,008) | ||||||
EV/EBITDA | ||||||||
Interest | 16 | 24 | ||||||
Interest/NOPBT | ||||||||